Eureka-DMA: an easy-to-operate graphical user interface for fast comprehensive investigation and analysis of DNA microarray data

BMC Bioinformatics

Sagi Abelson¹ 

[1] The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Technion, Israel

关键词: Gene ontology;    Pathways;    Differential expression;    Analysis;    Microarray;    Software;    GUI;   

Others  :  1087615
DOI  :  10.1186/1471-2105-15-53

 received in 2013-07-08, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

In the past decade, the field of molecular biology has become increasingly quantitative; rapid development of new technologies enables researchers to investigate and address fundamental issues quickly and in an efficient manner which were once impossible. Among these technologies, DNA microarray provides methodology for many applications such as gene discovery, diseases diagnosis, drug development and toxicological research and it has been used increasingly since it first emerged. Multiple tools have been developed to interpret the high-throughput data produced by microarrays. However, many times, less consideration has been given to the fact that an extensive and effective interpretation requires close interplay between the bioinformaticians who analyze the data and the biologists who generate it. To bridge this gap and to simplify the usability of such tools we developed Eureka-DMA — an easy-to-operate graphical user interface that allows bioinformaticians and bench-biologists alike to initiate analyses as well as to investigate the data produced by DNA microarrays.

Results

In this paper, we describe Eureka-DMA, a user-friendly software that comprises a set of methods for the interpretation of gene expression arrays. Eureka-DMA includes methods for the identification of genes with differential expression between conditions; it searches for enriched pathways and gene ontology terms and combines them with other relevant features. It thus enables the full understanding of the data for following testing as well as generating new hypotheses. Here we show two analyses, demonstrating examples of how Eureka-DMA can be used and its capability to produce relevant and reliable results.

Conclusions

We have integrated several elementary expression analysis tools to provide a unified interface for their implementation. Eureka-DMA's simple graphical user interface provides effective and efficient framework in which the investigator has the full set of tools for the visualization and interpretation of the data with the option of exporting the analysis results for later use in other platforms. Eureka-DMA is freely available for academic users and can be downloaded at http://blue-meduza.org/Eureka-DMA webcite.

【 授权许可】

   
2014 Abelson; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Yoo SM, Choi JH, Lee SY, Yoo NC: Applications of DNA microarray in disease diagnostics. J Microbiol Biotechnol 2009, 19(7):635-646.
• [2]Zarbl H: DNA microarrays: an overview of technologies and applications to toxicology. Curr Protoc Toxicol 2001, ((Supplement. 9)):1.4.2-1.4.16.
• [3]Sadi AM, Wang DY, Youngson BJ, Miller N, Boerner S, Done SJ, Leong WL: Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. BMC Cancer 2011, 11:253. 251-213 BioMed Central Full Text
• [4]Barrett T, Edgar R: Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 2006, 411:352-369.
• [5]Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N, Holloway E, Kapushesky M, Kemmeren P, Lara GG, et al.: ArrayExpress–a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 2003, 31(1):68-71.
• [6]Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193.
• [7]Archer KJ, Reese SE: Detection call algorithms for high-throughput gene expression microarray data. Brief Bioinform 2010, 11(2):244-252.
• [8]Kohane IS, Kho AT, Butte AJ: Microarrays for an integrative genomics. Cambridge, MA: MIT Press; 2003.
• [9]Cui X, Churchill GA: Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003, 4(4):210. BioMed Central Full Text
• [10]Mood AM, Graybill FA, Boes DC: Introduction to the theory of statistics. Third Edition. New York: McGraw-Hill; 1974.
• [11]Bar-Joseph Z, Gifford DK, Jaakkola TS: Fast optimal leaf ordering for hierarchical clustering. Bioinformatics 2001, 17(Suppl 1):S22-29.
• [12]Seber GAF: Multivariate observations. New York: John Wiley & Sons, Inc; 1984. ISBN 10: 047188104X
• [13]Spath HT, Goldschmidt J: Cluster dissection and analysis: theory, FORTRAN programs, examples. In Translated by J. Goldschmidt. New York: Halsted Press; 1985.
• [14]Michael E: Tipping CMB: probabilistic principal component analysis . J R Stat Soc Ser B (Stat Methodol) 1999, 61(3):611-622.
• [15]Alexander Ilin TR: Practical approaches to principal component analysis in the presence of missing values. J Mach Learn Res 2010, 11:1957-2000.
• [16]Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H: Potential responders to FOLFOX therapy for colorectal cancer by random forests analysis. Br J Cancer 2012, 106(1):126-132.
• [17]Breiman L: Random forests. Mach Learn 2001, vol. 45:5-32.
• [18]Rodriguez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25(11):1679-1691.
• [19]Krueger SK, Williams DE: Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005, 106(3):357-387.
• [20]Hyung SW, Lee MY, Yu JH, Shin B, Jung HJ, Park JM, Han W, Lee KM, Moon HG, Zhang H, et al.: A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers. Mol Cell Proteomics 2011, 10:M111.011023.
• [21]Han Y, Huang H, Xiao Z, Zhang W, Cao Y, Qu L, Shou C: Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One 2012, 7(12):e52745.
• [22]Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, Huang Y, Huang Q: Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One 2012, 7(12):e51256.
• [23]Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y, Morin PJ: Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res 2011, 4(1):21. BioMed Central Full Text
• [24]Krupp M, Maass T, Marquardt JU, Staib F, Bauer T, Konig R, Biesterfeld S, Galle PR, Tresch A, Teufel A: The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics 2011, 4:53. BioMed Central Full Text
• [25]Kubisch R, Meissner L, Krebs S, Blum H, Gunther M, Roidl A, Wagner E: A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl Oncol 2013, 6(1):1-9.
• [26]Pommerenke C, Wilk E, Srivastava B, Schulze A, Novoselova N, Geffers R, Schughart K: Global transcriptome analysis in influenza-infected mouse lungs reveals the kinetics of innate and adaptive host immune responses. PLoS One 2012, 7(7):e41169.